
In 2 pivotal phase 3 studies, all 5 readers hit sensitivity and specificity targets for florquinitau F 18 tau PET, including in patients with early symptomatic Alzheimer disease.
Many physicians are frustrated with government involvement, insurance companies, and reimbursement (or lack of reimbursement) systems. Does this prohibit you from helping your patients?



